contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


cessatech-ct001-soon-available-for-us-hospitals-in-collaboration-with-staq-pharma-for-acute-pain-management-in-children

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Cessatech operates in the pharmaceutical industry. The company specializes in research and development of analgesic nasal sprays that are also used for the treatment of acute pain conditions in children. In addition to the main business, associated ancillary services and related products are also offered. The business is operated globally with the largest presence in the Nordic market. Cessatech was founded in 2020 and is headquartered in Copenhagen.

Cessatech

 Successful completion of technology transfer of CT001 with STAQ Pharma supporting near term product availability CT001 is expected to reach the first hospitals in the US within the coming months...

<div class="abstract"><ul>	<li>Successful completion of technology transfer of CT001 with STAQ Pharma supporting near term product availability</li>	<li>CT001 is expected to reach the first hospitals in the US within the coming months</li>	<li>The finalisation of marketing and training material is currently in progress</li></ul></div>Copenhagen, Denmark - 31 October 2025 - Cessatech A/S ("Cessatech" or "the Company") today announces the successful completion of the technology transfer of CT001, marking a significant step towards making the product available to the first hospitals in the United States for acute pain management in children.This milestone represents an important advancement in Cessatech's mission to deliver innovative treatments that address unmet medical needs in paediatric care. The Company is collaborating closely with Ventis Pharma as its commercial partner and STAQ Pharma as the manufacturing partner to bring CT001 to the US market.Finalisation of marketing and training materials is currently underway, and CT001 is expected to become available to the first US hospitals in the coming months.In parallel, CT001 is being evaluated by the European Medicines Agency (EMA) through a Paediatric-Use Marketing Authorisation (PUMA) application - a dedicated regulatory pathway for medicines intended specifically for use in children. CT001 is being developed for the management of acute pain in children aged 1-17 years, with the aim of providing a safe, effective, and consistent treatment option where current alternatives remain limited.Comments from the CEO, Jes Trygved "Our collaboration with STAQ Pharma marks an important step in bringing CT001 to patients in the United States. STAQ Pharma's strong expertise in sterile manufacturing ensures a high-quality product for hospitals, and with marketing and training materials now being finalised, we are excited to soon make CT001 available for children in need of better pain management options."About STAQ Pharma and Ventis Pharma STAQ Pharma is a hospital-backed, FDA-registered outsourcing facility that manufactures nasal sprays and sterile compounded medications under cGMP standards. Its mission is to ensure safety, transparency, availability, and quality in delivering critical drugs to hospitals and care centers - especially in times of drug shortages. Ventis Pharma is a biopharmaceutical commercial company dedicated to developing and formulating innovative pain-management therapies. Its mission is to deliver safe, long-acting, low-toxicity solutions. <div></div>

Cessatech: CT001 soon available for US hospitals in collaboration with STAQ Pharma, for acute pain management in children